Biosimilars: Introduction, concerns, and opportunities

LCGC North America

Volumn 28, Issue 8, 2010, Pages 598-608

  Krull, Ira S ^a   Rathore, Anurag S ^b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78651319316     PISSN: 15275949     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Annex Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non Clinical and Clinical Issues-Guidance on Similar Medicinal Products Containing Somatropin. Committee for Medical Products for Human Use. EMEA/CHMP/94528/05 (CHMP adopted February 2006).
2. Annex Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non Clinical and Clinical Issues-Guidance on Similar Medicinal Products Containing Recombinant Erythropoietins. Committee for Medica l Products for Human Use. EMEA/CHMP/BMWP/94526/2005 (CHMP adopted March 2006).
3. Annex Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non Clinical and Clinical Issues-Guidance on Similar Medicinal Products Containing Recombinant Granulocyte-Colony Stimulating Factor. Committee for Medical Products for Human Use. EMEA/CHMP/BMWP/31329/2005 (CHMP adopted February 2006).
4. Annex Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non Clinical and Clinical Issues-Guidance on Similar Medicinal Products Containing Recombinant Human Soluble Insulin. Committee for Medical Products for Human Use. EMEA/CHMP/BMWP/32775/2005 (CHMP adopted February 2006).
5. A. J. Chirino and A. Mire-Sluis, Nat. Biotech. 22, 1383-1391 (2006).
6. Company website. http://www.drreddys.com/products/popups/reditux.htm
7. A. Covic, Nephrol. Dial. Transplant. 23, 3731-3737 (2008).
8. M. R. Gillick, J. Am. Geriatr. Soc. 54, 1442-1446 (2006).
9. Guideline on Similar Biological Medicinal Products. Committee for Medical Products for Human Use. CHMP/437/04 (CHMP adopted September, 2005).
10. Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues. Committee for Medical Products for Human Use. EMEA/CHMP/BWP/49348/05 (CH MP adopted February, 2006).
11. Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues. Committee for Medical Products for Human Use. EMEA/CHMP/42832/05 (CHMP adopted February, 2006).
12. Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins. Committee for Medical Products for Human Use. EMEA/CHMP/BMWP/14327/2006 (CHMP adopted December, 2007).
13. J. Harms et al., Biotechnol. Prog. 24, 655-662 (2008).
14. J. Hofgson, Nature Biotechnol. 27, 963-965 (2009).
15. S. Kozlowski and P. Swann, "Considerations for biotechnology product Quality by design", in Quality by Design for Biopharmaceuticals, A. S. Rathore and R. Mhatre, Eds. (Wiley Interscience, New York, 2009), pp. 9-30.
16. Note for Guidance on Planning Pharmaco-vigilance Activities. CPMP/ICH/5716/03 (CHMP adopted December, 2004).
17. P. O'Donnell, Appl. Clin. Trials 15, 38-42 (2006).
18. Office of Science and Technology Policy, Coordinated Framework for Regulation of Biotechnology, United States Regulatory Agencies Unified Biotechnology website [online], http://usbiotechreg.nbii.gov/Coordinated- Framework-1986-Federal-Register.html> (26 June, 1986).
19. S. S. Park, J. Pharm. Sci. 98, 1688-1699, (2009).
20. A. S. Rathore and H. Winkle, Nature Biotechnol. 27, 26-34 (2009).
21. A. S. Rathore, Trends Biotechnol. 27, 546-553 (2009).
22. A. S. Rathore, Trends Biotechnol. 27, 698-705 (2009).
23. A. Rosenberg, AAPS J. 8, E501-E507 (2006).
24. R. A. Rudick et al., Neurology 50, 1266-1272, (1998).
25. H. Schellekens, Eur. J. Hosp. Pharm. Sci., 3, 4347(2001).
26. R. J. Seely and J. Haury, Applications of failure modes and effects analysis to biotechnology manufacturing processes, in Process Validation in Manufacturing of Biopharmaceuticals, A. S. Rathore and G. Sofer, Eds. (Taylor & Francis, Boca Raton, Florida, 2005), pp. 13-30.
27. P. G. Swann et al., Current Opinion Immunol. 20, 493-499 (2008).
28. WHO Guideline on evaluation of similar biotherapeutic products (SBPs). 2009. http://www.who.int/biologicals/publications/trs/areas/biological- therapeutics/BS2110Dft-guidelines-Final-HK-IK-29July-09.pdf
29. J. Woodcock et al., Nat. Rev. Drug Discovery 6, 437-442 (2007).
30. C. K. Schneider and U. Kalinke, Nature Biotechnol. 26, 985-990 (2008).
31. P. van Hoek, J. Harms, X. Wang, and A. S. Rathore, Case Study on Definition of Design Space for a Microbial Fermentation Step, in Quality by Design for Biopharmaceuticals: Perspectives and Case Studies, A. S. Rathore and R. Mhatre, Eds. (Wiley Interscience, Hoboken, New Jersey, 2009) 85-109.